| Literature DB >> 26902998 |
Chenli Xie1,2, Xiaoliang Chen1,3, Fuman Qiu1, Lisha Zhang1, Di Wu1, Jiansong Chen1, Lei Yang1, Jiachun Lu1.
Abstract
Single nucleotide polymorphisms (SNPs) in the WW domain containing oxidoreductase (WWOX) gene were recently identified to be quantitative trait loci for lung function and thus likely to be susceptible biomarkers for COPD. However, the associations between WWOX SNPs and COPD risk are still unclear. Here, by conducting a two-center case-control study including 1511 COPD cases and 1677 controls and a family-based analysis comprising 95 nuclear pedigrees, we tested the associations between five SNPs that are rs10220974C >T, rs3764340C >G, rs12918952G >A, rs383362G >T, rs12828G >A of WWOX and COPD risk as well as the hereditary inclination of these loci among COPD families. We found that the SNP rs383362G >T was significantly associated with an increased risk of COPD in a T allele-number dependent-manner (OR = 1.30, 95%CI = 1.11-1.52). The T allele was more prone to over transmit to sick children and sibs than the G allele (Z = 2.900, P = 0.004). Moreover, the forced expiratory volume in one second/forced vital capacity (FEV1/FVC), FEV1/predicted-FEV1 and annual FEV1 also significantly decreased in the rs383362T carriers compared to the rs383362GG carriers. For other SNPs, no significant association was observed for COPD and pulmonary function. Taken together, our data demonstrated that the SNP rs383362G >T of WWOX plays a role in COPD inheritance.Entities:
Mesh:
Substances:
Year: 2016 PMID: 26902998 PMCID: PMC4763216 DOI: 10.1038/srep21716
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Genotype distributions of WWOX SNPs and their associations with COPD risk in the southern Chinese population.
| SNP | Location in gene | Case | Control | MAF | OR | OR | OR | OR | OR | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Case | Control | ||||||||||
| rs10220974C >T | Promoter | 748/252/25 | 806/231/24 | 0.290 | 0.147 | 0.132 | 1.20 (0.97–1.48) | 1.02 (0.57–1.83) | 1.13 (0.95–1.35) | 1.18 (0.96–1.45) | 0.98 (0.55–1.75) |
| rs3764340C >G | Exon | 832/186/7 | 837/214/10 | 0.390 | 0.098 | 0.110 | 0.92 (0.73–1.15) | 0.71 (0.26–1.94) | 0.91 (0.74–1.12) | 0.91 (0.73–1.13) | 0.73 (0.27–1.97) |
| rs12918952G >A | Exon | 884/137/4 | 910/144/7 | 0.688 | 0.071 | 0.075 | 1.01 (0.78–1.31) | 0.66 (0.19–2.29) | 0.98 (0.77–1.25) | 1.00 (0.77–1.29) | 0.66 (0.19–2.28) |
| rs383362G >T | 3′-UTR | 755/259/11 | 834/220/7 | 0.025 | 0.137 | 0.110 | 1.25 (1.01–1.55) | 2.23 (0.84–5.93) | 1.28 (1.06–1.56) | 1.28 (1.04–1.57) | 2.13 (0.80–5.64) |
| rs12828G >A | 3′-UTR | 474/463/88 | 473/489/99 | 0.692 | 0.312 | 0.324 | 0.94 (0.78–1.13) | 0.95 (0.69–1.31) | 0.96 (0.84–1.10) | 0.94 (0.79–1.12) | 0.98 (0.72–1.34) |
Abbreviation: MAF, minor allele frequency; OR , heterozygote versus wild-genotype homozygote; OR , variant homozygote versus wild-type homozygote; OR, OR , OR calculated by the additive, dominant and recessive model, respectively; 3′-UTR, 3′-untranslated region.
aWild-type homozygote/heterozygote/variant homozygote.
bThe observed genotype frequencies among the controls all matched the Hardy-Weinberg equilibrium in the control subjects (P > 0.05 for all).
cP values of a two-sided χ2 test for genotypes distribution between the cases and controls.
dMAF of the variant allele.
eData were calculated by the unconditional logistic regression, adjusted for age, sex, pack-years smoked, biomass as fuels and sample source region.
Association between the SNP rs383362G >T and COPD risk.
| Genotype/Allele | Case n (%) | Control n (%) | Crude OR (95%CI) | Adjusted OR (95%CI) |
|---|---|---|---|---|
| Eastern Chinese (Validation set) | ||||
| Total No. | 486 | 616 | ||
| rs383362G >T | ||||
| GG | 354(72.8) | 481(78.1) | 1.00 (ref.) | 1.00 (ref.) |
| TG | 126(16.0) | 132(21.4) | 1.30(0.98–1.72) | 1.32(0.99–1.75) |
| TT | 6(1.2) | 3(0.5) | 2.72(0.68–10.9) | 2.77(0.67–11.5) |
| | 0.075 | |||
| T allele | 0.142 | 0.112 | ||
| Additive model | ||||
| TT vs. TG vs. GG | 1.34(1.03–1.74) | 1.36(1.04–1.77) | ||
| Merged population | ||||
| Total No. | 1511 | 1677 | ||
| rs383362G >T | ||||
| GG | 1109(73.4) | 1315(78.4) | 1.00 (ref.) | 1.00 (ref.) |
| TG | 385(25.5) | 352(21.0) | 1.30(1.10–1.53) | 1.26(1.07–1.50) |
| TT | 17(1.1) | 10(0.6) | 2.02(0.92–4.42) | 2.39(1.07–5.35) |
| | 0.002 | |||
| T allele | 0.138 | 0.111 | ||
| Additive model | ||||
| TT vs. TG vs. GG | 1.31(1.13–1.53) | 1.30(1.11–1.52) | ||
aP values of a two-sided χ2 test for genotypes distribution between the cases and controls.
bAdjusted in a logistic regression model that included age, sex, pack-years smoked, biomass as fuels and sample source region.
Stratification analysis of the association between the SNP rs383362G >T and COPD risk in the merged population.
| Factors | Case ( | Control ( | Adjusted OR (95% CI) | |||||
|---|---|---|---|---|---|---|---|---|
| TT | TG | GG | TT | TG | GG | TT vs. TG vs. GG | ||
| Age (Years) | ||||||||
| ≤60 | 6 | 186 | 512 | 5 | 176 | 618 | 1.26(0.99–1.59) | 0.121 |
| >60 | 11 | 199 | 597 | 5 | 176 | 697 | 1.34(1.07–1.68) | |
| Sex | ||||||||
| Male | 11 | 230 | 642 | 4 | 216 | 763 | 1.30(1.06–1.61) | 0.991 |
| Female | 6 | 155 | 467 | 6 | 136 | 552 | 1.28(1.00–1.65) | |
| Smoking status | ||||||||
| Never | 10 | 203 | 584 | 8 | 212 | 806 | 1.32(1.07–1.62) | 0.825 |
| Ever | 7 | 182 | 525 | 2 | 140 | 509 | 1.28(1.00–1.65) | |
| Pack-years smoked | ||||||||
| ≥20 | 5 | 133 | 359 | 2 | 78 | 303 | 1.47(1.07–2.02) | 0.866 |
| <20 | 2 | 49 | 166 | 0 | 62 | 206 | 1.00(0.65–1.53) | |
| 0 | 10 | 203 | 584 | 8 | 212 | 806 | 1.32(1.07–1.63) | |
| Biomass as fuels | ||||||||
| No | 16 | 310 | 978 | 10 | 331 | 1226 | 1.23(1.04–1.45) | 0.021 |
| Yes | 1 | 75 | 131 | 0 | 21 | 89 | 2.32(1.28–4.22) | |
| GOLD Stages | ||||||||
| I | 5 | 158 | 458 | 10 | 352 | 1315 | 1.25(1.01–1.54) | |
| II | 6 | 151 | 437 | 1.29(1.05–1.59) | ||||
| III | 5 | 58 | 148 | 1.71(1.23–2.37) | ||||
| IV | 1 | 18 | 66 | 1.15(0.68–1.95) | ||||
aORs were adjusted for age, sex, pack-years smoked, biomass as fuels and sample source region in a logistic regression model.
bP value from the multiple interaction test.
FBAT analysis of effect of the WWOX SNPs on COPD risk in pedigree samples.
| SNP/Haplotype | FBAT | Logistic regression model | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Allele | Frequency | fam# | S | E(S) | Var(S) | Z | OR (95%CI) | ||
| rs383362G >T | G | 0.775 | 63 | 83 | 95.8 | 19.4 | −2.90 | 0.004 | 1.00 (ref.) |
| T | 0.225 | 63 | 49 | 36.2 | 19.4 | 2.90 | 0.004 | 2.04(1.41–2.95) | |
| rs10220974C >T | C | 0.859 | 51 | 74 | 75.0 | 14.7 | −0.261 | 0.794 | 1.00 (ref.) |
| T | 0.141 | 51 | 30 | 29.0 | 14.7 | 0.261 | 0.794 | 0.88(0.59–1.31) | |
| rs3764340C >G | C | 0.867 | 57 | 87 | 85.7 | 13.9 | 0.358 | 0.721 | 1.00 (ref.) |
| G | 0.133 | 57 | 27 | 28.3 | 13.9 | −0.358 | 0.721 | 1.29(0.85–1.96) | |
| rs12918952G >A | G | 0.886 | 58 | 88 | 92.3 | 17.0 | −1.04 | 0.299 | 1.00 (ref.) |
| A | 0.114 | 58 | 34 | 29.7 | 17.0 | 1.04 | 0.299 | 1.41(0.92–2.15) | |
| rs12828G >A | G | 0.762 | 69 | 113 | 105.2 | 22.1 | 1.67 | 0.096 | 1.00 (ref.) |
| A | 0.238 | 69 | 37 | 44.8 | 22.1 | −1.67 | 0.096 | 0.85(0.62–1.17) | |
| Haplotype | G-C | 0.706 | 69.0 | 100.0 | 109.0 | 22.3 | −1.92 | 0.055 | 1.00 (ref.) |
| T-C | 0.148 | 46.2 | 39.0 | 28.7 | 16.3 | 2.55 | 0.011 | 1.64(1.11–2.41) | |
| G-G | 0.107 | 40.3 | 16.0 | 19.6 | 9.4 | −1.18 | 0.239 | 1.15(0.73–1.84) | |
| T-G | 0.039 | 14.8 | 9.0 | 6.6 | 3.3 | 1.30 | 0.193 | 1.88(0.95–3.73) | |
Abbreviation: fam#: Number of nuclear families informative for the FBAT analysis.
S: Observed transmission for each allele; E(S) = Expected transmission for each allele.
Var(S): Variance of the observed transmission for each allele; Z score: Positive values indicate increased transmission and negative values indicate reduced transmission to affected individuals.
aHaplotypes generated by the rs383362G >T and rs3764340C >G polymorphisms. G-C: rs383362G-rs3764340C; T-C: rs383362T-rs3764340C; G-G: rs383362G-rs3764340G; T-G: rs383362T-rs3764340G.
Figure 1Effect of the WWOX SNP rs383362G >T on pulmonary function traits.
(A) Effect on prebronchodilator FEV1; (B) Effect on prebronchodilator FVC; (C) Effect on prebronchodilator FEV1/FVC; (D) Effect on prebronchodilator FEV1/predicted-FEV1; (E) Effect on annual average decline of prebronchodilator FEV1. Columns, mean from individuals’ lung function; FEV1: forced expiratory volume in 1 second; FVC: forced vital capacity. Bars, SD; The oneway ANOVA test was used to test the differences in pulmonary function between the rs383362G >T genotype carriers. As shown, the rs383362T variants significantly exerted lower FEV1 and FEV1/predicted-FEV1, and caused more annual average decline in FEV1 than the rs383362GG genotype.